Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orilissa

- PMLiVE

MHRA suspends new prescriptions of fibroid drug Esmya

The delay to Gedeon Richter's therapy follows reports of serious liver damage in some patients

- PMLiVE

AbbVie reports more solid data for would-be psoriasis blockbuster

Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

- PMLiVE

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

Moves a step closer to the rheumatoid arthritis market

- PMLiVE

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Judges praised the AbbVie project for its impressive reach

- PMLiVE

AbbVie named PMEA 2017 Company of the Year

Sees off strong competition from Amgen and Sanofi

- PMLiVE

Boehringer claims EU okay for Humira biosimilar

But won’t launch before expiration of the respective SPC for adalimumab in October 2018

- PMLiVE

Boehringer builds evidence base for its Humira biosimilar

Cyltezo shows clinical equivalence to AbbVie's blockbuster in a late-stage trial

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

AbbVie risankizumab trials set up psoriasis filing – and a market battle

Competes against blockbusters Stelara and Humira

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links